m+Medelevator.RU
← Поиск публикаций
JACC. Case reports · 2026

Cyclophosphamide-Induced Hemorrhagic Myocarditis.

Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Jibawi Rivera Rade R, Harmon David M, Herrmann Joerg, Pellikka Patricia A

Аннотация

BACKGROUND: Cyclophosphamide is a widely used chemotherapeutic agent with a spectrum of toxicities, including a rare drug-related hemorrhagic myocarditis.

CASE SUMMARY: A 63 -year-old male with myelofibrosis underwent haploidentical stem cell transplantation with 95 mg/kg cyclophosphamide conditioning. He developed tachycardia, lower-extremity edema, and pulmonary congestion 8 days later. Troponin-T was 512 ng/L, and N-terminal pro-brain natriuretic peptide was 20,142 pg/mL, each previously normal. Electrocardiogram showed low-voltage QRS complexes in limb leads. Echocardiography demonstrated significant left ventricular wall thickening (17 mm), preserved left ventricular ejection fraction (54%), and decreased global longitudinal strain (-9%), all previously normal. Cardiac magnetic resonance imaging suggested myocardial edema and inflammation. Left ventricular T2∗ value near 20 ms suggested intramyocardial hemorrhage. Volume overload and supraventricular arrhythmias were managed conservatively.

DISCUSSION: To our knowledge, there are no reported cases of nonfatal cyclophosphamide-induced hemorrhagic myocarditis at a dose <100 mg/kg.

TAKE-HOME MESSAGE: An expedited multimodal cardiac imaging approach is warranted when this rare cardiotoxicity is suspected.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты